Breathing, Lung Function and Bronchitis: 7 Things You Need to Know — From Spirometry to Pranayama to the Antibiotic Myth

By Dr. Narayan Rout | Author | Researcher |    Holistic Health Series  ·  36 min read  ·  Published: July 01, 2026

Contents In This Research Pillar

Table of Contents

1. Introduction
2. 1. How the Lungs Actually Work — The Mechanics Most People Were Never Taught
   1. The two muscle groups that matter most for breathing
3. 2. What Spirometry Measures — FVC, FEV1, and Peak Flow Explained in Plain Language
   1. FVC — Forced Vital Capacity
   2. FEV1 — Forced Expiratory Volume in One Second
   3. PEFR — Peak Expiratory Flow Rate
4. 3. Acute Bronchitis — What It Is, What It Isn’t, and Why Antibiotics Are Wrong
   1. What the randomised trial data says about treatments for acute bronchitis
5. 4. Chronic Bronchitis — The COPD Connection, What Causes It, and What Can and Cannot Be Reversed
   1. The India-specific pollution context
   2. What can and cannot be done
6. 5. What Ayurveda Called Tamaka Shwasa — When Ancient Classification Met Modern Pathology
   1. Kaphaja Kasa — the cough classification
   2. Vasaka to bromhexine — a direct pharmacological lineage
7. 6. Pranayama and Lung Function — What 12 Weeks of Structured Breathing Actually Does to Your Spirometry
   1. The specific pranayama techniques and what the trials showed
   2. Pranayama vs Buteyko — a specific RCT comparison
   3. Pranayama evidence summary table
8. 7. A Practical Framework for Protecting and Strengthening Your Lungs at Every Life Stage
9. The Quest Sage Insight
10. What You Can Do With This
11. Conclusion: The Lungs Are Trainable, Bronchitis Is Mostly Viral, and Both Facts Are Underused
12. Frequently Asked Questions: Breathing, Lung Function and Bronchitis
13. References and Sources
14. Further Reading on Related Topic

We breathe roughly 20,000 times a day without thinking about it. That number alone should be enough to establish breathing as the single most repeated action in a human life — and yet most people have only the vaguest idea of how the lungs actually do what they do, what can go wrong with them, or what the evidence says about keeping them functional well into old age. Bronchitis, one of the most common reasons people visit a doctor in any given year, is genuinely misunderstood — not just by patients but by a significant proportion of prescribing clinicians, as the data on inappropriate antibiotic use makes embarrassingly clear.

Here’s the thing: breathing is trainable. The lungs are not passive bellows. They are dynamic organs with measurable, modifiable function — and both the randomised trial literature on pranayama and the ancient Indian classification of respiratory disease in Charaka Samhita arrive at the same underlying insight: how you breathe, practiced deliberately over time, physically changes what your lungs can do. That convergence is the animating idea of this article.

We’ll move through seven evidence-grounded sections: the basic mechanics of how the lungs work; what spirometry measures and why FEV1 matters; the acute bronchitis picture and the antibiotic myth; chronic bronchitis and its COPD connection; Ayurveda’s two-thousand-year-old classification of bronchitis-like disease; what randomised pranayama trials actually show; and a practical framework for protecting and building pulmonary health. The goal throughout is the same as always: the most useful, honest, evidence-grounded account of a topic that affects every living person with every breath they take.

|| प्राणायामेन युक्तेन सर्वरोगक्षयो भवेत् ||

“Through the right practice of pranayama, all diseases may be diminished.” — A classical assertion not of magical cure but of the genuine therapeutic value of structured breathing practice, consistent with what modern RCTs have since confirmed.

— Hatha Yoga Pradipika 2.16 — classical yoga text on pranayama and health

The lungs don’t suck air in. That’s the first thing worth getting straight. Breathing is driven by pressure differential, created by muscular effort, and the lungs simply follow. The diaphragm — a dome-shaped muscle sitting below the lungs — is the primary driver of every quiet breath. When it contracts, it flattens, pulling the chest cavity downward and enlarging its volume. That enlargement drops the pressure inside the chest below atmospheric pressure, and air rushes in to equalise. When the diaphragm relaxes, lung elasticity does the work of expelling air passively, without muscular effort — at least at rest.

Air entering through the nose or mouth travels down the trachea, splits into the two main bronchi (one per lung), and then into progressively smaller bronchioles until it reaches the alveoli — roughly 300 million tiny air sacs whose combined surface area is approximately 70 square metres in a healthy adult. That is roughly the size of a singles tennis court, folded into a space you can hold in your two hands. Gas exchange happens across the alveolar membrane, which is just one cell thick: oxygen diffuses across into surrounding capillaries, carbon dioxide diffuses back in the other direction, and the cycle of oxygenated blood leaving the lungs begins.

Quiet breathing uses the diaphragm almost exclusively. Deeper breathing — during exercise, deliberate practice, or respiratory distress — recruits the external intercostal muscles (between the ribs) for inhalation and the internal intercostals and abdominal muscles for forceful exhalation. This is why respiratory muscle training through deep breathing practice, including structured pranayama, has a measurable physiological target: the strength and coordination of these secondary respiratory muscles directly influences peak expiratory flow rate and the total volume of air that can be forcefully moved, both of which are measured by spirometry.

The other structural component worth understanding is the mucus clearance system. The airways are lined with a mucociliary escalator — cilia, which are tiny hair-like projections, beating in coordinated waves to move mucus upward and out of the lungs. When this system is overwhelmed by infection, irritant inhalation, or excessive mucus production, the result is the productive cough that characterises bronchitis. The cough is not itself the disease; it is the body’s amplified backup clearance mechanism when the mucociliary escalator is outpaced.

Spirometry is the primary clinical tool for measuring lung function, and two numbers from it come up in virtually every respiratory medicine conversation. Understanding them gives you the ability to read and interpret your own results rather than waiting for someone to translate them.

FVC is the total volume of air you can exhale after taking the deepest possible breath in. It represents the total working volume of the lungs available for each breath cycle. A reduced FVC can suggest either that something is restricting the lung from expanding fully (restrictive disease — fibrosis, obesity, neuromuscular conditions) or that severe air trapping from obstructive disease is preventing complete emptying.

FEV1 is how much of that total volume you can get out in the first second of a maximal forced exhalation. In a healthy adult, that’s typically around 75-80% of FVC — so if FVC is 5 litres, you’d expect FEV1 to be roughly 3.7-4 litres. The key diagnostic number is the FEV1/FVC ratio: a ratio below 0.7 (70%) in the presence of symptoms indicates obstructive airflow limitation, which is the hallmark finding in COPD and asthma. Restrictive disease, by contrast, typically shows a reduced FVC with a normal or even elevated FEV1/FVC ratio — the lung is smaller in total but airflow through it isn’t impeded.

PEFR measures the fastest speed at which you can exhale — in litres per minute — and is most commonly used for ongoing asthma monitoring with a handheld peak flow meter. It is effort-dependent and operator-sensitive, which is why spirometry with a trained technician is preferred for diagnostic purposes. But PEFR measurements at home over time give a useful picture of how well-controlled a person’s airways are day to day.

Measure	What It Tests	Normal Range	Low Value Suggests
FVC	Total exhaled volume after max breath in	Typically 3.5–5 L (age/sex dependent)	Restriction or severe air trapping
FEV1	Volume exhaled in first second of forced exhalation	~75–80% of FVC	Obstructive airflow limitation
FEV1/FVC ratio	Speed of airflow relative to total volume	>0.70 in adults	Obstruction (COPD, asthma) if <0.70
PEFR	Maximum speed of exhalation (L/min)	450–600 L/min (healthy adult)	Airway narrowing, poor asthma control

Source: StatPearls Physiology, Lung; Frontiers in Physiology 2022.

Acute bronchitis is one of the most commonly mismanaged conditions in outpatient medicine — not because it’s complicated but because of a gap between what the evidence clearly says and what actually gets prescribed. The 2025 rapid evidence review in American Family Physician is unambiguous: acute bronchitis is a self-limiting disease, accounting for more than 3 million outpatient visits in the United States annually, and the evidence does not support antibiotics for it.

More than 90% of acute bronchitis cases are caused by viruses — rhinovirus, influenza A and B, adenovirus, respiratory syncytial virus (RSV), and various coronavirus strains including COVID-19 variants. Bacteria cause fewer than 10% of cases, and even then, antibiotic treatment rarely changes the course in otherwise healthy adults. The differential diagnosis the 2025 review emphasises includes exacerbations of pre-existing asthma or COPD, COVID-19, influenza, pertussis (whooping cough), and community-acquired pneumonia — and the clinical question is not whether to give antibiotics but whether the presentation might be one of these other conditions where different treatment is needed.

A well-designed multicentre RCT in 416 adults (Llor et al.) comparing ibuprofen, amoxicillin-clavulanic acid, and placebo for acute bronchitis with discoloured sputum found no significant difference between the three groups in the number of days with frequent cough — the antibiotic performed no better than placebo. The CHEST clinical practice guidelines, using GRADE evidence grading, found insufficient high-quality evidence to support antitussives, honey, antihistamines, anticholinergics, oral NSAIDs, or inhaled or oral corticosteroids for acute bronchitis. Beta-agonists have been studied in small trials for acute bronchitis with wheeze and produce mixed results — they may offer modest benefit in a subgroup of patients with demonstrable bronchospasm but are not recommended routinely.

The antibiotic-prescribing problem deserves to be said plainly: NCQA data show that 65-80% of acute bronchitis cases in US outpatient settings are still being prescribed antibiotics, despite clinical guidelines having been clear for decades that this is wrong. More than 28% of all outpatient antibiotic prescriptions are unnecessary, and acute bronchitis is the leading driver. More than 35,000 people die in the US annually from antibiotic-resistant infections — a figure the WHO projects will increase significantly. Every unnecessary antibiotic course prescribed for a viral bronchitis case contributes to this trajectory.

What actually does help in acute bronchitis

• Rest and adequate hydration — supporting the mucociliary clearance system’s normal function.
• Warm steam or humidified air — evidence-limited but widely used for symptomatic mucus relief with no adverse effects.
• Honey — specifically for cough symptom relief in children (evidence supports modest benefit), with caution: not for infants under 12 months.
• Time — the most evidence-consistent treatment available; most acute bronchitis resolves within 7-21 days without any pharmaceutical intervention.
• Seek evaluation if: high fever persisting beyond 3 days, coughing up blood, shortness of breath at rest, symptoms beyond 3 weeks, or any suspicion of pneumonia (fever, pleuritic chest pain, significantly reduced breath sounds on one side).

Chronic bronchitis is a different condition from acute bronchitis in almost every way that matters clinically. The definition is precise: a productive cough present for at least three months in each of two consecutive years, without another identifiable cause. It is not a single episode or a seasonal pattern — it is a persistent, progressive structural change in the airways.

The underlying mechanism is hypertrophy and hyperplasia of the bronchial mucous glands — the glands swell and multiply, producing excessive mucus that obstructs the airways, damages ciliary function, and creates the chronic cough-and-expectoration cycle that defines the condition. The cause is, in the vast majority of cases, one of two things: prolonged cigarette smoke exposure, or prolonged occupational or environmental inhalation of particulate matter and chemical irritants. Chronic bronchitis is classified as a component of COPD, alongside emphysema, and the two often coexist in long-term smokers.

For Indian and South Asian readers, the environmental and occupational driver of chronic bronchitis deserves specific attention: indoor air pollution from biomass fuel combustion — wood, crop residue, dung — in poorly ventilated cooking environments is a major contributor to COPD in non-smoking populations in India, disproportionately affecting women who spend significant time near traditional chulhas or open fires. This is not a minor or niche risk: the Global Burden of Disease data consistently rank India among the highest-burden COPD countries globally, and household air pollution is one of the primary drivers outside smoking exposure.

The honest clinical position is that established chronic bronchitis and COPD cannot be cured — the structural changes to the bronchial glands and alveolar walls do not fully reverse. What changes is the trajectory: cessation of smoking (or removal from the exposure driving the condition) is the single most effective intervention available, slowing the rate of FEV1 decline from roughly 60 mL per year in active smokers to close to the 30 mL per year decline seen in non-smokers. Bronchodilators (short and long-acting beta-agonists and anticholinergics) improve symptoms and exercise capacity. Pulmonary rehabilitation — structured supervised exercise with breathing retraining — has the strongest evidence base for improving quality of life and exercise tolerance in COPD. Corticosteroids reduce exacerbation frequency in moderate-to-severe COPD. Oxygen therapy in hypoxaemic patients reduces mortality. What does not clearly change the underlying disease: most herbal supplements, dietary interventions, or unstructured breathing exercises, though structured pranayama does have a separate evidence base reviewed in Section 6.

Before there was a spirometer, before FEV1 was a concept, before anyone had named a bronchus or mapped an alveolus, the classical Ayurvedic physician Charaka described a respiratory condition with clinical precision that holds up surprisingly well against modern bronchitis pathology.

Charaka Samhita Chikitsa Sthana Chapter 17, Shloka 62 describes Tamaka Shwasa: “Tamakashwasaha kaphaavrita vayuprabhavaha, krichchhraswasa, peenasa, kasa, urahshoola, aruchi” — a condition of obstructed, difficult breathing (krichchhraswasa) arising from Prana Vayu blocked by aggravated Kapha, accompanied by nasal congestion (peenasa), cough (kasa), chest pain (urahshoola), and loss of appetite (aruchi). Ashtanga Hridayam Nidana Sthana 4/5 adds: “Sleshmoparodhaat shvasa kasau cha jaayate” — from Kapha-obstruction arise dyspnoea and cough. This is Ayurveda’s description of obstructive respiratory disease — mucus-driven, airway-obstructing, producing both breathlessness and productive cough — written roughly two thousand years before bronchoscopy confirmed the mechanism.

Kaphaja Kasa specifically names the productive, mucus-laden cough arising from vitiated Kapha dosha — the dosha associated in classical Ayurveda with the qualities of heaviness, coldness, and density. The Ashtanga Hridayam describes it with symptoms of thick whitish expectoration, heaviness in the chest, and diminished appetite — symptoms consistent with the productive cough of chronic bronchitis and its associated systemic effects. The classical treatment approach uses herbs and therapies with hot potency (Ushna Virya) and pungent or astringent tastes, specifically to counter Kapha’s cold and heavy qualities: a logical internal consistency that maps onto the modern understanding of mucolytics and expectorants.

The most striking convergence between classical Ayurvedic respiratory medicine and modern pharmacology is not conceptual but chemical. Adhatoda vasica (Vasa), prescribed for thousands of years in Ayurvedic formulations for Kaphaja Kasa and Tamaka Shwasa, contains vasicine — an alkaloid with well-documented bronchodilatory and mucolytic properties. Vasicine was the direct pharmacological precursor from which the synthetic drug bromhexine was developed, which in turn is metabolised to ambroxol in the body. Both bromhexine and ambroxol are widely used modern mucolytics for respiratory tract conditions including bronchitis. The line from Charaka’s herbal prescription to a modern pharmacy shelf is unbroken.

|| श्लेष्मोपरोधात् श्वास-कासौ च जायते ||

“From the obstruction of Kapha arise both dyspnoea and cough.” — A classical Ayurvedic description of the bronchitis mechanism: mucus obstruction producing both breathlessness and productive cough, documented roughly two thousand years before bronchoscopy confirmed the mechanism.

— Ashtanga Hridayam, Nidana Sthana 4/5

The herb Adhatoda vasica has been prescribed in Ayurvedic respiratory formulations for two thousand years. Modern pharmacology didn’t discover a new principle when it derived bromhexine from vasicine — it confirmed one. That is what genuine convergence looks like: not a metaphor, not an analogy, but a chemical molecule tracing a direct line from an ancient herbal text to a modern pharmacy shelf.

The claim that pranayama improves lung function is common in wellness content. What’s less common is a clear account of what the actual randomised trial evidence says — what changed, in which patients, over what timeframe, and measured how. This section provides that account.

A 2025 systematic review and meta-analysis of randomised controlled trials of yoga and pranayama on pulmonary function in clinical populations (PMC12451276) pooled results across multiple studies and found statistically significant improvements in three key spirometry parameters: FVC% (forced vital capacity as percentage of predicted), FEV1 (absolute value, weighted mean difference 0.47 L, p < 0.00001), and FEV1% (FEV1 as percentage of predicted). The proposed mechanism: pranayama practice — particularly slow, controlled breathing — strengthens the respiratory muscles (diaphragm, intercostals, abdominals), improves lung compliance and elasticity, and likely reduces resting respiratory rate, allowing more complete alveolar ventilation per breath.

A randomised controlled trial comparing slow pranayama (Nadi Shodhana or alternate nostril breathing, Pranav pranayama, Savitri pranayama — all slow, controlled techniques) versus fast pranayama (Kapalabhati, Bhastrika, Kukkriya — all rapid, forceful techniques) in 91 healthy volunteers over 12 weeks found improvements in commonly measured pulmonary function parameters in both groups, with fast pranayama producing more pronounced improvement in FEV1/FVC ratio, PEFR, and FEF25-75 (the flow rate measured at 25-75% of FVC, which reflects small airway function). Slow pranayama produced improvements in breathing economy and reported respiratory comfort. No significant change was observed in the untreated control group.

A separate randomised controlled trial in 90 asthma patients on inhaled corticosteroids comparing Eucapnic Buteyko breathing versus a Pink City Lung Exerciser designed to mimic pranayama (slow exhalation at 1:2 inspiration-expiration ratio) versus placebo over 6 months found that neither technique significantly changed FEV1 or bronchial responsiveness — suggesting the spirometry improvements observed in healthy subjects or less severe patients may not translate directly to changed airway responsiveness in established asthma. The Buteyko group did show symptom improvement and reduced bronchodilator use. This is an important nuance: pranayama’s spirometry benefits appear more consistent in healthy subjects and populations without established severe airway disease than in patients with already significantly compromised airways.

Technique	Trial Type	Duration	What Improved
Yoga + pranayama (mixed)	Meta-analysis (RCTs), PMC12451276	4 weeks–1 year	FVC%, FEV1, FEV1% — statistically significant
Slow pranayama (Nadi Shodhana, Savitri)	RCT, 91 healthy volunteers	12 weeks	Pulmonary function parameters — significant improvement
Fast pranayama (Kapalabhati, Bhastrika)	RCT, 91 healthy volunteers	12 weeks	FEV1/FVC, PEFR, FEF25-75 — more pronounced than slow
Pink City Lung Exerciser (pranayama mimic)	RCT, 90 asthma patients	6 months	No significant change in FEV1 or bronchial responsiveness

Sources: PMC12451276 (2025 meta-analysis); PubMed 25558130 (RCT, 91 volunteers); PMC1746772 (Buteyko vs pranayama RCT).

Pulling seven sections together into something actionable. Lung health is not a single intervention — it’s a layered set of habits, practices, and informed decisions that compound over time. The framework here divides by what to avoid, what to practise, and when to evaluate.

What to avoid — the evidence-backed harms list

• Cigarette smoke — the single largest modifiable risk for chronic bronchitis and COPD; even secondhand smoke exposure meaningfully accelerates FEV1 decline.
• Indoor biomass combustion without adequate ventilation — a major driver of non-smoking COPD in South Asia; ventilated cooking environments are not optional, they are respiratory medicine.
• Occupational inhalant exposure without appropriate protection — silica dust, coal dust, chemical fumes, and construction particulates all have documented links to chronic bronchial and alveolar damage.
• Unnecessary antibiotics for viral respiratory infections — every unnecessary course contributes to resistance, delivers adverse effects, and provides no clinical benefit for the condition being treated.

What to practise — the evidence-backed positives

• Structured pranayama — 12 weeks of 30-minute sessions, three times per week, is the timeframe at which RCT-measured spirometry improvements became statistically significant; Nadi Shodhana and Kapalabhati are the best-evidenced techniques for healthy adults.
• Aerobic exercise — cardiovascular fitness training demonstrably improves exercise capacity and respiratory muscle efficiency, even when it doesn’t change resting spirometry values in healthy adults.
• Nasal breathing during rest and gentle exercise — nasal passages warm, humidify, and filter air, reducing the volume of cold, dry, unfiltered air reaching the bronchial mucosa; chronic mouth breathing bypasses this system.
• Adequate hydration — supports mucociliary clearance; mucus viscosity increases with dehydration, impairing the cilia’s ability to move it upward and out.

When to get evaluated — the red flag list

• Any cough lasting beyond 3 weeks — the diagnostic boundary beyond which acute bronchitis should no longer be the primary assumption.Coughing up blood — haemoptysis always warrants investigation.
• Shortness of breath at rest or on minimal exertion — particularly if it is new, progressive, or accompanied by chest tightness or wheeze.
• A baseline spirometry reading if you have smoked for 10+ years, work in a dusty or chemical environment, or have chronic respiratory symptoms — COPD is frequently underdiagnosed until FEV1 has already fallen significantly.
• Symptoms of pneumonia — high fever, unilateral chest pain that worsens with breathing, significantly reduced breath sounds on one side — which require urgent evaluation and are not the same clinical picture as bronchitis.

The thing that strikes me most about researching this topic is how differently the modern clinical world and the classical Indian world arrived at the same practical wisdom about breath. Modern pulmonology came from the spirometer outward — measuring first, understanding mechanism later, building protocols from trial data. Ayurveda came from observation inward — watching how patients breathed, how their cough sounded, what relieved it, and building a system of classification from careful clinical attention over centuries.

Both arrived at the same two conclusions: first, that what obstructs the airway (mucus, in Kapha obstruction; inflamed bronchial walls, in modern pathology) is the core problem, not the cough itself, which is a response. Second, that deliberate, structured breathing — pranayama in the classical system, respiratory muscle training in the modern one — genuinely changes what the lungs can do. That convergence is not coincidental. It reflects careful, sustained observation of the same physical system by two different traditions that didn’t know about each other.

The antibiotic misuse story is the shadow side of this. Modern medicine, which produced the spirometer and the randomised trial and the GRADE evidence system, is simultaneously prescribing antibiotics for viral bronchitis at a rate of 65-80%, despite its own guidelines clearly prohibiting it. Ancient Ayurvedic medicine, working without laboratory diagnostics, nonetheless classified bronchitis accurately enough to develop an herbal formula containing a molecule that modern pharmacology would later synthesise and sell globally. Both traditions have things to teach. And both traditions can fail their own standards.

• If you or someone in your family gets an acute cough with bronchitis symptoms, do not request or accept antibiotics unless a physician specifically identifies a bacterial infection or another condition requiring antibiotic treatment. Understand that the evidence is clear: antibiotics do not help acute viral bronchitis.
• Begin a 12-week pranayama practice — start with Nadi Shodhana (alternate nostril breathing) for 10 minutes, building to 30 minutes, three times weekly — and request a baseline spirometry before you start and after 12 weeks to see your own measurable change.
• If you cook indoors with biomass fuel or work in a dusty or chemical environment, treat ventilation or respiratory protection as non-optional medical infrastructure rather than comfort preference.
• Learn the five red flags in this article (cough beyond 3 weeks, haemoptysis, rest dyspnoea, new wheeze, unilateral chest signs) and use them to decide when a respiratory symptom warrants clinical evaluation rather than watchful waiting.
• If you have smoked for more than 10 years or have had chronic respiratory symptoms for multiple years, ask your doctor specifically for spirometry with FEV1 and FEV1/FVC ratio — COPD is frequently underdiagnosed until significant lung function has already been lost.

Seven sections, one overarching point: the lungs are dynamic organs that respond to how they’re used, and most of the practical decision-making around respiratory health is simpler and clearer than popular understanding suggests. Acute bronchitis is almost always viral, self-limiting, and not requiring antibiotics — a fact that clinical guidelines have been clear about for decades and that prescribing patterns have persistently ignored. Chronic bronchitis is a structural disease requiring exposure removal above all else, not managed by supplements or breathing exercises alone, though pulmonary rehabilitation has genuine evidence behind it. Pranayama, practised for 12 weeks in structured sessions, produces measurable spirometry improvements in healthy subjects and many clinical populations — not through mystical means but through straightforward respiratory muscle training and improved breathing mechanics. And Ayurveda’s Tamaka Shwasa, written two thousand years ago with no access to a spirometer, described bronchitis accurately enough to produce an herbal prescription containing a molecule that modern pharmacology later isolated and sold as bromhexine.

The governing thesis this article opened with holds: the lungs are trainable, and how you breathe, practised deliberately over time, physically changes what they can do. That is both ancient Indian wisdom and confirmed modern science — and unlike most convergences, this one comes with a randomised controlled trial and a measurable change in FEV1 to prove it.

StatPearls. Physiology, Lung. NCBI Bookshelf, NBK545177. https://www.ncbi.nlm.nih.gov/books/NBK545177/

WisTech Open. (2024). 6.2 Review of Anatomy and Physiology of the Respiratory System. Health Alterations. https://wtcs.pressbooks.pub/healthalts/chapter/6-2-review-of-anatomy-and-physiology-of-the-respiratory-system/

Zhao Z, Sang L, Oh TI. (2022). CardioPulmonary Physiology: Novel Approaches to Pulmonary Function and Critical Care. Frontiers in Physiology. DOI: 10.3389/fphys.2021.825098. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762205/

Mulhem E, Patalinghug E, Eraqi H. (2025, March). Acute Bronchitis: Rapid Evidence Review. American Family Physician, 111(3):214-217. PMID: 40106287. https://pubmed.ncbi.nlm.nih.gov/40106287/

StatPearls. Acute Bronchitis. NCBI Bookshelf, NBK448067. Last Updated March 9, 2024. https://www.ncbi.nlm.nih.gov/books/NBK448067/

Michigan Quality Improvement Consortium. (2024, April). Management of Uncomplicated Acute Bronchitis in Adults. Based on ACCP Evidence-Based Clinical Practice Guidelines 2006. https://www.mahp.org/wp-content/uploads/2024/04/mqicmanagementofuncomplicatedacutebronchitisinadultsFINAL2024.pdf

Llor C, et al. Randomised controlled trial: ibuprofen vs amoxicillin-clavulanic acid vs placebo in acute bronchitis with coloured sputum. CHEST. 2020 Feb. https://journal.chestnet.org/article/S0012-3692(20)30329-9/fulltext

NCQA. Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB) — HEDIS Measure. 2024-2025. https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/avoidance-of-antibiotic-treatment-for-acute-bronchitis-bronchiolitis-aab/

CMS MIPS Quality Measure #116. (2025). Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis. https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2025_Measure_116_MIPSCQM.pdf

BCBS Illinois. (2025, August 20). Avoid Antibiotics for Acute Bronchitis and Other Viruses. https://www.bcbsil.com/provider/education/education-reference/news/2025/8-20-2025-avoid-antibiotics-for-acute-bronchitis-and-other-viruses

Cleveland Clinic. (2023). Chronic Bronchitis: Causes, Symptoms, Diagnosis & Treatment. https://my.clevelandclinic.org/health/diseases/24645-chronic-bronchitis

Ayurved Healing. (2026, February 23). Ayurvedic Respiratory Health: Herbs and Therapies. Tamaka Shwasa, bromhexine-vasicine connection. https://www.ayurvedhealing.com/ayurvedic-respiratory-health-asthma-allergy-herbs/

Adyant Ayurveda. (2025). Ayurvedic Treatment for Bronchitis. Charaka Samhita CS 17/62; AH Ni. 4/5. https://adyantayurveda.com/bronchitis/

Adyant Ayurveda. (2025). Ayurvedic Treatment for Respiratory Problems — Shwasa Roga classification. https://adyantayurveda.com/ayurvedic-treatment-for-respiratory-problems/

The Ayurveda Experience. (2025, March 7). How To Boost Lung Health As Per Ayurveda? Pranayama, Shwasa Roga, Kasa classification. https://blog.theayurvedaexperience.com/how-to-boost-lung-health-as-per-ayurveda/

Boas H, Tan L, Ren CL. (2025, September 11). Pediatric Pulmonology Year in Review 2024: Physiology. DOI: 10.1002/ppul.71269. https://www.ncbi.nlm.nih.gov/pmc/articles/

PMC12424278/PMC12451276. (2025). Impact of yoga on pulmonary functions in clinical population: A systematic review and meta-analysis of randomized controlled trials. FEV1 WMD 0.47 L, p < 0.00001. https://pmc.ncbi.nlm.nih.gov/articles/PMC12451276/

PubMed 25558130. Comparative effect of 12 weeks of slow and fast pranayama training on pulmonary function in young, healthy volunteers: A randomized controlled trial. 91 volunteers, SPG vs FPG vs control. https://pubmed.ncbi.nlm.nih.gov/25558130/

Thorax 2003;58:649-50. PMC1746772. Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomised controlled trial. 90 asthma patients, 6 months. https://pmc.ncbi.nlm.nih.gov/articles/PMC1746772/

Rout, N. (2026). How Much Water Should You Really Drink? 7 Evidence-Based Answers. TheQuestSage.com, TQS-2026-116. https://thequestsage.com/how-much-water-drink-daily-evidence/

Rout, N. (2026). The Complete Guide to Grains: 7 Evidence-Based Categories. TheQuestSage.com, TQS-2026-119. https://thequestsage.com/best-grains-health-body-evidence-guide/

P8 Holistic Health Series — Related Articles

• Hydropathy: 7 Evidence-Based Ways Water Becomes Medicine (TheQuestSage.com, TQS-2026-154) — The mucociliary system needs hydration; this is the complete water-as-medicine companion article.
• Warm, Cold or Normal Water Bath? 8 Evidence-Based Answers (TheQuestSage.com, TQS-2026-118) — Includes the Ayurvedic prohibition on hot water to the head, relevant for respiratory steam therapy.
• Why Preventive Medicine Is the Future: 5 Evidence-Based Reasons (TheQuestSage.com, TQS-2026-113) — The respiratory health framework in this article is exactly what preventive medicine looks like in practice.

---